Q-omics provides the consensus-scored LINC00319 profile across patient tissues and cancer cell-line models. LINC00319 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, LINC00319 is differentially expressed in 6, with the highest sampling consensus in LUAD. Additionally, LINC00319 RNA expression shows 6,036 significant pathway-activity associations, with the highest sampling consensus in OV. Together, these results highlight MESO, LUAD, and OV as cancer lineages where LINC00319 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00319 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00319 survival associations across molecular data types. LINC00319 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00319 RNA expression–survival associations across cancer types. High LINC00319 expression shows unfavorable associations in MESO, DLBC, COAD, TGCT, LUSC and THCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for LINC00319 RNA expression.
This table summarizes LINC00319 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00319. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00319 shows lower tumor expression in STAD and KICH and higher tumor expression in LUAD, HNSC, LUSC and BRCA. The LUAD box plot shows higher LINC00319 RNA expression in tumor versus normal tissue (log2 FC = +0.055, t-test p = .001).
This table shows molecular features associated with LINC00319 in patient tissues and cancer cell lines. In patient samples, LINC00319 shows the broadest associations at the RNA and protein expression levels, with OV recurring as the lineage with the largest associated feature set.
